Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions

Novo Nordisk's (NVO) Wegovy pill, launched in early January, has seen over 600,000 prescriptions written within three months, including more than 3,000 in its first week. This surge reflects a growing demand for GLP-1 treatments as patients previously deterred by injection methods now gravitate towards the oral option. The pill is priced between $149 to $299 per month, which analysts attribute to its early success. Despite this positive start, Novo's stock price remains under pressure as competition from Eli Lilly's newly approved GLP-1 product, Foundayo, arises.